Understanding Polymorphic Control of Pharmaceuticals Using Imidazolium-Based Ionic Liquid Mixtures as Crystallization Directing Agents
Imidazolium-based room temperature ionic liquids (RTILs) were tested to assess their ability to control molecular polymorphic behavior. Mixtures of RTILs with distinct cation/anion combinations revealed promising capabilities in directing the crystallization process toward less stable polymorphs. In...
Gespeichert in:
Veröffentlicht in: | Crystal growth & design 2017-02, Vol.17 (2), p.428-432 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 432 |
---|---|
container_issue | 2 |
container_start_page | 428 |
container_title | Crystal growth & design |
container_volume | 17 |
creator | Martins, Inês C. B Gomes, José R. B Duarte, M. Teresa Mafra, Luís |
description | Imidazolium-based room temperature ionic liquids (RTILs) were tested to assess their ability to control molecular polymorphic behavior. Mixtures of RTILs with distinct cation/anion combinations revealed promising capabilities in directing the crystallization process toward less stable polymorphs. In our tests, gabapentin (GBP) neuroleptic drug was used as a case study, as it is a well know polymorphic active pharmaceutical ingredient. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated through RTILs. Forms were maintained over time, once they were kept soaked, opening new perspectives for the method presented here. Molecular dynamics (MD) simulations clearly supported the results. In this work the polymorphic behavior of GBP is controlled recurring to the use of different pure imidazolium-based RTILs or mixtures, as crystallization solvents. Molecular dynamics simulations clearly supported the results showing that specific H(acidic(C4/C6mim))···O(carboxylate) interaction between GBP and RTILs drives the formation of Form IV. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated. These results showed the importance of these “directing agents” in the polymorphic process as well as the importance of using MD simulations in predicting the “designed” crystallization environment for the “desired” polymorph. |
doi_str_mv | 10.1021/acs.cgd.6b01798 |
format | Article |
fullrecord | <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_acs_cgd_6b01798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>b970581785</sourcerecordid><originalsourceid>FETCH-LOGICAL-a258t-6865d6c6eb349d9e9d37874f7bd9728053c9e037055c39136413c016e03f48f43</originalsourceid><addsrcrecordid>eNp1kD9PwzAQxS0EEqUws3pHae04dpyxhH-ViuhA58i1ndZVEhfbkWg_AJ8bRy0j053u3nt3-gFwj9EEoxRPhfQTuVETtkY4L_gFGGGa8iSniF7-9Rkn1-DG-x1CKGeEjMDPqlPa-SA6ZboNXNrm0Fq33xoJS9sFZxtoa7jcCtcKqftgpGg8XPlBPG-NEkfbmL5NHoXXCs5tF40L89UbBd_Nd-id9lB4WLpDvNE05iiCsR18Mk7LMITMNroL_hZc1TFY353rGKxenj_Lt2Tx8TovZ4tEpJSHhHFGFZNMr0lWqEIXiuQ8z-p8rYo85YgSWWhEckSpJAUmLMNEIszirM54nZExmJ5ypbPeO11Xe2da4Q4VRtWAsYoYq4ixOmOMjoeTY1jsbO-6-N-_6l_0ZHgv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Understanding Polymorphic Control of Pharmaceuticals Using Imidazolium-Based Ionic Liquid Mixtures as Crystallization Directing Agents</title><source>American Chemical Society Journals</source><creator>Martins, Inês C. B ; Gomes, José R. B ; Duarte, M. Teresa ; Mafra, Luís</creator><creatorcontrib>Martins, Inês C. B ; Gomes, José R. B ; Duarte, M. Teresa ; Mafra, Luís</creatorcontrib><description>Imidazolium-based room temperature ionic liquids (RTILs) were tested to assess their ability to control molecular polymorphic behavior. Mixtures of RTILs with distinct cation/anion combinations revealed promising capabilities in directing the crystallization process toward less stable polymorphs. In our tests, gabapentin (GBP) neuroleptic drug was used as a case study, as it is a well know polymorphic active pharmaceutical ingredient. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated through RTILs. Forms were maintained over time, once they were kept soaked, opening new perspectives for the method presented here. Molecular dynamics (MD) simulations clearly supported the results. In this work the polymorphic behavior of GBP is controlled recurring to the use of different pure imidazolium-based RTILs or mixtures, as crystallization solvents. Molecular dynamics simulations clearly supported the results showing that specific H(acidic(C4/C6mim))···O(carboxylate) interaction between GBP and RTILs drives the formation of Form IV. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated. These results showed the importance of these “directing agents” in the polymorphic process as well as the importance of using MD simulations in predicting the “designed” crystallization environment for the “desired” polymorph.</description><identifier>ISSN: 1528-7483</identifier><identifier>EISSN: 1528-7505</identifier><identifier>DOI: 10.1021/acs.cgd.6b01798</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Crystal growth & design, 2017-02, Vol.17 (2), p.428-432</ispartof><rights>Copyright © 2017 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a258t-6865d6c6eb349d9e9d37874f7bd9728053c9e037055c39136413c016e03f48f43</citedby><cites>FETCH-LOGICAL-a258t-6865d6c6eb349d9e9d37874f7bd9728053c9e037055c39136413c016e03f48f43</cites><orcidid>0000-0001-5993-1385 ; 0000-0003-0994-1352</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.cgd.6b01798$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.cgd.6b01798$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids></links><search><creatorcontrib>Martins, Inês C. B</creatorcontrib><creatorcontrib>Gomes, José R. B</creatorcontrib><creatorcontrib>Duarte, M. Teresa</creatorcontrib><creatorcontrib>Mafra, Luís</creatorcontrib><title>Understanding Polymorphic Control of Pharmaceuticals Using Imidazolium-Based Ionic Liquid Mixtures as Crystallization Directing Agents</title><title>Crystal growth & design</title><addtitle>Cryst. Growth Des</addtitle><description>Imidazolium-based room temperature ionic liquids (RTILs) were tested to assess their ability to control molecular polymorphic behavior. Mixtures of RTILs with distinct cation/anion combinations revealed promising capabilities in directing the crystallization process toward less stable polymorphs. In our tests, gabapentin (GBP) neuroleptic drug was used as a case study, as it is a well know polymorphic active pharmaceutical ingredient. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated through RTILs. Forms were maintained over time, once they were kept soaked, opening new perspectives for the method presented here. Molecular dynamics (MD) simulations clearly supported the results. In this work the polymorphic behavior of GBP is controlled recurring to the use of different pure imidazolium-based RTILs or mixtures, as crystallization solvents. Molecular dynamics simulations clearly supported the results showing that specific H(acidic(C4/C6mim))···O(carboxylate) interaction between GBP and RTILs drives the formation of Form IV. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated. These results showed the importance of these “directing agents” in the polymorphic process as well as the importance of using MD simulations in predicting the “designed” crystallization environment for the “desired” polymorph.</description><issn>1528-7483</issn><issn>1528-7505</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kD9PwzAQxS0EEqUws3pHae04dpyxhH-ViuhA58i1ndZVEhfbkWg_AJ8bRy0j053u3nt3-gFwj9EEoxRPhfQTuVETtkY4L_gFGGGa8iSniF7-9Rkn1-DG-x1CKGeEjMDPqlPa-SA6ZboNXNrm0Fq33xoJS9sFZxtoa7jcCtcKqftgpGg8XPlBPG-NEkfbmL5NHoXXCs5tF40L89UbBd_Nd-id9lB4WLpDvNE05iiCsR18Mk7LMITMNroL_hZc1TFY353rGKxenj_Lt2Tx8TovZ4tEpJSHhHFGFZNMr0lWqEIXiuQ8z-p8rYo85YgSWWhEckSpJAUmLMNEIszirM54nZExmJ5ypbPeO11Xe2da4Q4VRtWAsYoYq4ixOmOMjoeTY1jsbO-6-N-_6l_0ZHgv</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Martins, Inês C. B</creator><creator>Gomes, José R. B</creator><creator>Duarte, M. Teresa</creator><creator>Mafra, Luís</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-5993-1385</orcidid><orcidid>https://orcid.org/0000-0003-0994-1352</orcidid></search><sort><creationdate>20170201</creationdate><title>Understanding Polymorphic Control of Pharmaceuticals Using Imidazolium-Based Ionic Liquid Mixtures as Crystallization Directing Agents</title><author>Martins, Inês C. B ; Gomes, José R. B ; Duarte, M. Teresa ; Mafra, Luís</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a258t-6865d6c6eb349d9e9d37874f7bd9728053c9e037055c39136413c016e03f48f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martins, Inês C. B</creatorcontrib><creatorcontrib>Gomes, José R. B</creatorcontrib><creatorcontrib>Duarte, M. Teresa</creatorcontrib><creatorcontrib>Mafra, Luís</creatorcontrib><collection>CrossRef</collection><jtitle>Crystal growth & design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martins, Inês C. B</au><au>Gomes, José R. B</au><au>Duarte, M. Teresa</au><au>Mafra, Luís</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding Polymorphic Control of Pharmaceuticals Using Imidazolium-Based Ionic Liquid Mixtures as Crystallization Directing Agents</atitle><jtitle>Crystal growth & design</jtitle><addtitle>Cryst. Growth Des</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>17</volume><issue>2</issue><spage>428</spage><epage>432</epage><pages>428-432</pages><issn>1528-7483</issn><eissn>1528-7505</eissn><abstract>Imidazolium-based room temperature ionic liquids (RTILs) were tested to assess their ability to control molecular polymorphic behavior. Mixtures of RTILs with distinct cation/anion combinations revealed promising capabilities in directing the crystallization process toward less stable polymorphs. In our tests, gabapentin (GBP) neuroleptic drug was used as a case study, as it is a well know polymorphic active pharmaceutical ingredient. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated through RTILs. Forms were maintained over time, once they were kept soaked, opening new perspectives for the method presented here. Molecular dynamics (MD) simulations clearly supported the results. In this work the polymorphic behavior of GBP is controlled recurring to the use of different pure imidazolium-based RTILs or mixtures, as crystallization solvents. Molecular dynamics simulations clearly supported the results showing that specific H(acidic(C4/C6mim))···O(carboxylate) interaction between GBP and RTILs drives the formation of Form IV. For the first time, pure “bulk” GBP Form IV, a highly unstable polymorph, was isolated. These results showed the importance of these “directing agents” in the polymorphic process as well as the importance of using MD simulations in predicting the “designed” crystallization environment for the “desired” polymorph.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.cgd.6b01798</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-5993-1385</orcidid><orcidid>https://orcid.org/0000-0003-0994-1352</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1528-7483 |
ispartof | Crystal growth & design, 2017-02, Vol.17 (2), p.428-432 |
issn | 1528-7483 1528-7505 |
language | eng |
recordid | cdi_crossref_primary_10_1021_acs_cgd_6b01798 |
source | American Chemical Society Journals |
title | Understanding Polymorphic Control of Pharmaceuticals Using Imidazolium-Based Ionic Liquid Mixtures as Crystallization Directing Agents |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T16%3A26%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20Polymorphic%20Control%20of%20Pharmaceuticals%20Using%20Imidazolium-Based%20Ionic%20Liquid%20Mixtures%20as%20Crystallization%20Directing%20Agents&rft.jtitle=Crystal%20growth%20&%20design&rft.au=Martins,%20Ine%CC%82s%20C.%20B&rft.date=2017-02-01&rft.volume=17&rft.issue=2&rft.spage=428&rft.epage=432&rft.pages=428-432&rft.issn=1528-7483&rft.eissn=1528-7505&rft_id=info:doi/10.1021/acs.cgd.6b01798&rft_dat=%3Cacs_cross%3Eb970581785%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |